U.S. Stem Cell, Inc. (USRM)

U.S. Stem Cell Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Revenue	0.08	0.2	0.28	3.07	6.7
Revenue Growth (YoY)	-59.13%	-27.55%	-90.98%	-54.15%	21.38%
Cost of Revenue	0.02	0.05	0.06	1.34	2.11
Gross Profit	0.06	0.15	0.21	1.74	4.59
Selling, General & Admin	1.78	2.28	2.61	4.45	5.68
Research & Development	0	0	0	0	0.01
Other Operating Expenses	0	-0.15	0	0.7	0
Operating Expenses	1.78	2.28	2.61	5.15	5.69
Operating Income	-1.72	-2.14	-2.4	-3.42	-1.1
Interest Income	0.69	1	0.49	0.98	0
Interest Expense	0.69	1	0.49	0.98	1.44
Other Expense / Income	1.14	1.15	0.49	0.42	-1.44
Pretax Income	-2.86	-3.29	-2.89	-3.84	-2.16
Income Tax	0.45	1	0.49	1.2	1.06
Net Income	-3.31	-4.29	-3.38	-5.04	-2.16
Shares Outstanding (Basic)	592	461	429	398	366
Shares Outstanding (Diluted)	592	461	429	398	366
Shares Change	28.38%	7.34%	7.85%	8.86%	18.33%
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01
Free Cash Flow	-0.3	-1.06	-0.48	-1.38	0.6
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	0.00
Gross Margin	71.03%	74.08%	76.86%	56.54%	68.50%
Operating Margin	-2096.90%	-1063.94%	-866.24%	-111.22%	-16.38%
Profit Margin	-4028.60%	-2135.78%	-1219.42%	-163.89%	-32.24%
Free Cash Flow Margin	-371.55%	-527.00%	-172.83%	-44.85%	8.99%
EBITDA	-1.72	-2.29	-2.42	-2.96	-0.64
EBITDA Margin	-2096.88%	-1139.37%	-874.67%	-96.20%	-9.60%
Depreciation & Amortization	0.69	0.98	0.45	0.24	0.21
EBIT	-2.41	-3.26	-2.87	-3.2	-0.85
EBIT Margin	-2932.15%	-1626.24%	-1036.13%	-104.09%	-12.69%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.